ClinicalTrials.Veeva

Menu

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

L

Laval University

Status and phase

Completed
Phase 3

Conditions

Human Papillomavirus Vaccines

Treatments

Biological: Gardasil and Gardasil-9

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT03431246
CÉ: 2017-3036-21

Details and patient eligibility

About

This study will assess the immunogenicity of one dose of Gardasil and one dose of Gardasil-9

Full description

This is a one group exploratory study.

The main objective of this study is to assess the persistance of anti-HPV after a single dose Gardasil and the effect of one dose of Gardasil-9 when administered 3-8 years later.

Enrollment

32 patients

Sex

Female

Ages

12 to 18 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: Have received a single dose of Gardasil 3-8 years before recruitement.

Exclusion Criteria: Immunossupressed or blood coagulation problems

Trial design

Primary purpose

Prevention

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

32 participants in 1 patient group

Gardasil and Gardasil-9
Experimental group
Treatment:
Biological: Gardasil and Gardasil-9

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems